Plasma testosterone content of male patients with Parkinson's disease during L-dopa treatment with or without dopadecarboxylase inhibitor.
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004295:Dihydroxyphenylalanine / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D005500:Follow-Up Studies; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology / Q000627:therapeutic use*; D007989:Libido / Q000187:drug effects; D008297:Male; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D013268:Stimulation, Chemical; D013739:Testosterone / Q000097:blood*; D013997:Time Factors
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004338:Drug Combinations; D006834:Hydrazines; D013739:Testosterone; D004295:Dihydroxyphenylalanine